Enovis 

€37.4
14
+€0.8+2.19% Thursday 06:03

統計

當日最高
37.4
當日最低
37.4
52週最高
-
52週最低
-
成交量
0
平均成交量
-
市值
2.04B
市盈率
-
股息收益率
-
股息
-

即將到來

股息

0%股息收益率
10年增長
N/A
5年增長率
N/A
3年增長率
N/A
1年增長率
N/A

收益

6Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.37
0.51
0.65
0.79
預期每股收益
0.62
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 C520.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Show more...
首席執行官
Mr. Matthew L. Trerotola
員工
6550
國家
US
ISIN
US1940145022
WKN
000A3DHHV

上市公司